Xcout IntelMadrigal Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Madrigal Pharmaceuticals, Inc. among pharmaceuticals companies — ranked by similarity to what Madrigal Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Madrigal Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. at a glance
Madrigal Pharmaceuticals, Inc. is a pharmaceuticals company headquartered in West Conshohocken, United States. It is publicly listed (MDGL) with a market capitalisation of $11.3B. Xcout tracks 20 named people at Madrigal Pharmaceuticals, Inc., including William J. Sibold (Chief Executive Officer, President & Director).
Madrigal Pharmaceuticals, Inc. leadership
- William J. SiboldChief Executive Officer, President & Director
- Bill SiboldCEO
- Mardi C. DierExecutive Vice President & Chief Financial Officer
- Carole HuntsmanExecutive Vice President & Chief Commercial Officer
- David SoergelExecutive VP & Chief Medical Officer
- Shannon KelleyExecutive Vice President, Chief Legal Officer & Corporate Secretary
14 more named people on record for Madrigal Pharmaceuticals, Inc., with roles, board committees and tenure — see the full roster →
Top 12 Madrigal Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Madrigal Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar pharmaceuticals company
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
Similar pharmaceuticals company
Hepion Pharmaceuticals, Inc., a U.S.-based biopharmaceutical entity, is dedicated to developing therapeutic interventions for chronic hepatic ailments. Central to their efforts is Rencofilstat, a cyclophilin inhibitor that has successfully concluded Phase 2a clinical trials. This compound operates by disrupting multiple pathological pathways implicated in the worsening of liver disease. It is currently progressing through clinical development for non-alcoholic steatohepatitis (NASH) and is additionally being explored in nonclinical research for its potential to reduce liver fibrosis and lessen hepatocellular carcinoma tumor loads in experimental models of NASH. Moreover, Rencofilstat has exhibited antiviral properties against hepatitis B, C, and D viruses through diverse mechanisms. The company, established in 2013 and situated in Edison, New Jersey, rebranded as Hepion Pharmaceuticals, Inc. in July 2019, having previously operated as ContraVir Pharmaceuticals, Inc.
Similar pharmaceuticals company
Poxel S.A. is a biopharmaceutical firm in the clinical development phase, dedicated to discovering innovative therapies for metabolic disorders, particularly type 2 diabetes and various liver conditions. Its primary asset, TWYMEEG (Imeglimin), is an oral medication that addresses mitochondrial dysfunction and has already received approval in Japan for managing type 2 diabetes. Poxel is also advancing PXL770, an activator of the adenosine monophosphate-activated protein kinase (AMPK) enzyme, currently in Phase 2a trials for various chronic metabolic diseases, notably liver ailments like non-alcoholic steatohepatitis (NASH). Furthermore, the company holds licensing agreements: one with Enyo Pharma S.A.S. for a farnesoid X receptor (FXR) agonist, now in a Phase 2a study for hepatitis B and NASH, and another with DeuteRx LLC for PXL065, a mitochondrial pyruvate carrier inhibitor undergoing Phase 1 evaluation specifically for NASH treatment. Established in 2009, Poxel S.A. operates from its headquarters in Lyon, France.
Similar pharmaceuticals company
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Similar pharmaceuticals company
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
Similar pharmaceuticals company
SCOHIA PHARMA, Inc. is a clinical-stage specialty bioventure headquartered in Fujisawa, Japan. Established in 2017, the company focuses its research and development on lifestyle-related diseases including cardiovascular, metabolic, and renal disorders.
Similar pharmaceuticals company
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
Similar pharmaceuticals company
Sparrow Pharmaceuticals, Inc. is a Boston-based biopharmaceutical company focused on developing targeted cardiometabolic therapeutics. The company aims to address conditions such as diabetes and endocrine diseases with precision therapies.
Similar pharmaceuticals company
Esperion Therapeutics, Inc. operates as a pharmaceutical company primarily focused on developing and commercializing medications designed to manage elevated low-density lipoprotein (LDL) cholesterol levels in patients. Its flagship pharmaceutical products include NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) in tablet form. These treatments are prescribed for individuals suffering from atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). Additionally, Esperion has established strategic licensing and collaborative partnerships with Daiichi Sankyo Europe GmbH and Serometrix to obtain rights to an oral, small molecule PCSK9 inhibitor program. The company was founded in 2008 and its principal offices are located in Ann Arbor, Michigan.
Biotechnology & Pharmaceuticals
CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Newark, California, focused on developing therapies for liver and other chronic diseases before being acquired by Gilead Sciences.
Similar pharmaceuticals company
vTv Therapeutics Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on creating orally administered treatments, with a significant emphasis on diabetes. Its pipeline features lead candidates such as TTP399, an oral, small-molecule, liver-specific glucokinase activator targeting Type 1 diabetes. Another key investigational drug is HPP737, an oral phosphodiesterase type 4 (PDE4) inhibitor that does not cross the blood-brain barrier (non-CNS penetrant), designed to treat inflammatory conditions and psoriasis. Beyond these, vTv Therapeutics' broader clinical portfolio includes: TTP273, an oral small-molecule GLP-1 receptor agonist addressing postprandial glucose excursions in cystic fibrosis-related diabetes. HPP3033, which employs a non-electrophilic strategy to activate the Nrf2 pathway for chronic conditions linked to oxidative stress. Azeliragon, a RAGE antagonist being evaluated for inflammatory lung disorders, notably severe COVID-19, alongside pancreatic and breast cancers. HPP971, an Nrf2 activator aimed at renal diseases, developed in collaboration with pharmaceutical partners. Furthermore, vTv holds a licensing agreement with Reneo Pharmaceuticals, Inc. for the development and commercialization of its peroxisome proliferation-activated receptor delta agonist program, which features the compound HPP593. The company has also established various other licensing and research collaborations with entities such as Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., Newsoara Biopharma Co., Ltd., JDRF International, and Novo Nordisk A/S. Established in 2015, vTv Therapeutics is headquartered in High Point, North Carolina, and operates as a subsidiary of MacAndrews & Forbes Incorporated.
Similar pharmaceuticals company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the exploration, advancement, and marketing of innovative therapies rooted in RNA interference (RNAi) technology. The company's research pipeline for RNAi treatments targets a diverse array of medical conditions, encompassing inherited disorders, cardiovascular and metabolic diseases, hepatic infections, and illnesses affecting the central nervous system (CNS) and eyes. Alnylam's commercialized products include ONPATTRO (patisiran), an injectable lipid complex prescribed for adults experiencing polyneuropathy due to hereditary transthyretin-mediated amyloidosis. Also marketed are GIVLAARI, used to treat acute hepatic porphyria (AHP) in adult patients, and OXLUMO (lumasiran), indicated for primary hyperoxaluria type 1 (PH1). In terms of its developmental programs, the company is progressing several candidates: Givosiran, for the treatment of AHP in adolescent patients. Patisiran, being investigated for transthyretin amyloidosis (ATTR amyloidosis) when accompanied by cardiomyopathy. Cemdisiran, aimed at complement-mediated diseases. ALN-AAT02, for liver disease associated with AAT deficiency. ALN-HBV02, targeting chronic hepatitis B virus infection. Zilebesiran, for the management of hypertension. ALN-HSD, for non-alcoholic steatohepatitis (NASH). Fitusiran, addressing hemophilia and various rare bleeding disorders. Inclisiran, developed to treat hypercholesterolemia. Lumasiran, for advanced PH1 and recurrent kidney stones. Vutrisiran, currently in Phase 3 clinical trials for ATTR amyloidosis. Alnylam Pharmaceuticals maintains strategic alliances with several key players in the industry. It collaborates with Regeneron Pharmaceuticals, Inc. on the discovery, development, and commercialization of RNAi therapeutics for ocular and CNS targets. Another significant partnership exists with Sanofi Genzyme, focusing on the broader development and commercialization of RNAi treatments. Furthermore, the company holds licensing and collaboration agreements with Novartis AG, Vir Biotechnology, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and PeptiDream, Inc. The company was established in 2002 and operates from its headquarters in Cambridge, Massachusetts.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Madrigal Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Madrigal Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →